Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

NCT05493293 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
82
Enrollment
INDUSTRY
Sponsor class

Stopped The long-term extension study was terminated because the parent study NBI-921352-FOS2021 (NCT05159908) failed to meet its primary endpoint.

Conditions

Interventions

Sponsor

Neurocrine Biosciences